Laboratory Co. of America (NYSE:LH) PT Raised to $249.00 at Barclays

Laboratory Co. of America (NYSE:LH - Free Report) had its target price upped by Barclays from $234.00 to $249.00 in a research note issued to investors on Friday, Benzinga reports. Barclays currently has an equal weight rating on the medical research company's stock.

Other equities analysts have also issued research reports about the stock. Robert W. Baird raised their price objective on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the company an "outperform" rating in a research report on Friday. Truist Financial lifted their price target on shares of Laboratory Co. of America from $255.00 to $275.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. UBS Group increased their price objective on Laboratory Co. of America from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Bank of America lifted their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "buy" rating in a report on Monday, August 5th. Finally, Jefferies Financial Group upped their target price on Laboratory Co. of America from $245.00 to $265.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $253.54.

Laboratory Co. of America Price Performance

Shares of Laboratory Co. of America stock traded down $1.44 on Friday, hitting $228.63. The company had a trading volume of 819,191 shares, compared to its average volume of 668,948. Laboratory Co. of America has a 52 week low of $191.97 and a 52 week high of $239.50. The company has a market cap of $19.20 billion, a PE ratio of 43.11, a PEG ratio of 1.70 and a beta of 1.05. The business has a 50-day simple moving average of $222.58 and a 200-day simple moving average of $212.26. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.88 and a quick ratio of 0.77.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.48 by $0.02. The firm had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.26 billion. Laboratory Co. of America had a return on equity of 15.39% and a net margin of 3.60%. The firm's quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company posted $3.38 EPS. Research analysts expect that Laboratory Co. of America will post 14.55 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Tuesday, November 26th will be paid a $0.72 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $2.88 annualized dividend and a yield of 1.26%. Laboratory Co. of America's dividend payout ratio is presently 54.55%.

Insider Buying and Selling at Laboratory Co. of America

In other news, EVP Lance Berberian sold 12,093 shares of the company's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $229.10, for a total value of $2,770,506.30. Following the transaction, the executive vice president now directly owns 15,921 shares of the company's stock, valued at approximately $3,647,501.10. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Lance Berberian sold 12,093 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $229.10, for a total value of $2,770,506.30. Following the transaction, the executive vice president now owns 15,921 shares in the company, valued at approximately $3,647,501.10. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kerrii B. Anderson sold 586 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $225.00, for a total transaction of $131,850.00. Following the transaction, the director now directly owns 14,722 shares in the company, valued at approximately $3,312,450. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,679 shares of company stock valued at $6,946,306 in the last quarter. Company insiders own 0.85% of the company's stock.

Institutional Investors Weigh In On Laboratory Co. of America

Large investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Laboratory Co. of America by 3.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 16,581 shares of the medical research company's stock valued at $3,622,000 after acquiring an additional 550 shares during the last quarter. Aviance Capital Partners LLC grew its holdings in Laboratory Co. of America by 7.7% during the first quarter. Aviance Capital Partners LLC now owns 3,808 shares of the medical research company's stock valued at $832,000 after purchasing an additional 272 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new position in shares of Laboratory Co. of America in the first quarter valued at approximately $3,431,000. Valeo Financial Advisors LLC lifted its stake in shares of Laboratory Co. of America by 9.3% in the first quarter. Valeo Financial Advisors LLC now owns 7,823 shares of the medical research company's stock worth $1,709,000 after buying an additional 666 shares during the last quarter. Finally, Hudson Capital Management LLC boosted its holdings in shares of Laboratory Co. of America by 7.0% during the 1st quarter. Hudson Capital Management LLC now owns 15,821 shares of the medical research company's stock worth $3,456,000 after buying an additional 1,031 shares during the period. 95.94% of the stock is currently owned by institutional investors.

Laboratory Co. of America Company Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.